Clinical Considerations for Biosimilars in Rheumatology Practice: Integrating Into Practice

In this downloadable slideset, Jonathan Kay, MD, explores key concepts including immunogenicity, switching, and interchangeability of biosimilars.
Stanley B. Cohen, MD
Jonathan Kay, MD
Kenneth G. Saag, MD, MSc
Format: Microsoft PowerPoint (.ppt)
File Size: 862 KB
Released: November 21, 2017

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by independent educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc.
Sandoz Inc., a Novartis Division

Related Content

Commentary by Dr. Vinod Chandran on using interleukin inhibitors secukinumab and guselkumab for axial manifestations of psoriatic arthritis, from CCO

Vinod Chandran, MBBS, MD, DM, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 11, 2021 Expired: January 10, 2022

Commentary from Dr Jim Treat on counseling parents and children about pros and cons of systemic therapy for pediatric plaque psoriasis, from CCO

person default Jim Treat, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 8, 2021 Expired: January 7, 2022

CME for CCO on when to use interleukin inhibitors in psoriatis arthritis: biologic DMARD or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab

Vinod Chandran, MBBS, MD, DM, PhD person default Alexis Ogdie, MD, MSCE Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: December 29, 2020 Expired: December 28, 2021

CCO slides on when to use interleukins inhibitors in psoriatis arthritis: biologic dmard or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab.

Vinod Chandran, MBBS, MD, DM, PhD person default Alexis Ogdie, MD, MSCE Released: December 29, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue